SuperworthStoke Therapeutics market cap STOK
Share price times shares outstanding: what the whole company sells for, since 2019.
- Today, Oct 23, 2026
- $1.6B
- Highest close in our data
- $2.3B
- Jan 2021
Stoke Therapeutics is worth $1.6B at the close on Oct 23, 2026, at $25.04 a share.
That is down 9% over the last year and up 93% over five years.
Its highest close in our data was $2.3B in Jan 2021.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $1.6B | $1.6B | $2.2B | −11% |
| 2025 | $1.8B | $321.2M | $1.9B | +211% |
| 2024 | $585.8M | $208.1M | $846.9M | +149% |
| 2023 | $234.9M | $149.1M | $574.5M | −35% |
| 2022 | $363.9M | $289M | $975.1M | −59% |
| 2021 | $882.6M | $722.6M | $2.3B | −57% |
| 2020 | $2.1B | $667.4M | $2.1B | +138% |
| 2019 | $870M | $671.7M | $1.2B | n/a |
Against its peers
Companies in Drug Manufacturers - General nearest Stoke Therapeutics' size, closest first, today.
| Company | Market cap |
|---|---|
| STOKStoke Therapeutics | $1.6B |
| PAHCPhibro Animal Health | $1.6B |
| ANIPANI Pharmaceuticals | $1.7B |
| ANABAnaptysbio | $1.5B |
| PCRXPacira BioSciences | $1.5B |
| HRMYHarmony Biosciences | $2.1B |
| OMEROmeros | $1.2B |
| PBHPrestige Consumer Healthcare | $2.3B |
| AMPHAmphastar Pharmaceuticals | $1.1B |
| NRIXNurix Therapeutics | $2.8B |
| ABUSArbutus Biopharma | $831M |
| Peer median | $1.5B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Stoke Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.